HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,460 | +5.9% | 300 | 0.0% | 0.00% | – |
| Q2 2023 | $10,821 | -5.6% | 300 | 0.0% | 0.00% | – |
| Q1 2023 | $11,457 | -84.5% | 300 | -76.9% | 0.00% | -100.0% |
| Q4 2022 | $73,970 | +45.0% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $51,000 | -10.5% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $57,000 | +307.1% | 1,300 | +271.4% | 0.00% | – |
| Q3 2021 | $14,000 | -12.5% | 350 | 0.0% | 0.00% | – |
| Q2 2021 | $16,000 | -100.0% | 350 | -79.4% | 0.00% | -100.0% |
| Q1 2021 | $70,874,000 | +472393.3% | 1,700 | +385.7% | 0.00% | – |
| Q4 2020 | $15,000 | -64.3% | 350 | -85.4% | 0.00% | -100.0% |
| Q4 2019 | $42,000 | +13.5% | 2,400 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $37,000 | -24.5% | 2,400 | -16.5% | 0.00% | -50.0% |
| Q2 2019 | $49,000 | -14.0% | 2,875 | -8.1% | 0.00% | -33.3% |
| Q3 2018 | $57,000 | +7.5% | 3,130 | -0.3% | 0.00% | 0.0% |
| Q2 2018 | $53,000 | – | 3,140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
| Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
| 2Xideas AG | 600,799 | $22,950,522 | 2.54% |
| BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
| Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
| Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
| Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
| Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
| EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
| First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |